428 related articles for article (PubMed ID: 37492827)
21. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
[TBL] [Abstract][Full Text] [Related]
22. Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
Gallego-Colon E; Daum A; Yosefy C
Eur J Pharmacol; 2020 Jul; 878():173114. PubMed ID: 32302598
[TBL] [Abstract][Full Text] [Related]
23. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
24. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical Data.
Durairaj A; Sabates A; Nieves J; Moraes B; Baum S
Curr Treat Options Cardiovasc Med; 2017 Aug; 19(8):58. PubMed ID: 28639183
[TBL] [Abstract][Full Text] [Related]
25. PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction: a systematic review and network meta-analysis.
Khan SU; Yedlapati SH; Lone AN; Hao Q; Guyatt G; Delvaux N; Bekkering GET; Vandvik PO; Riaz IB; Li S; Aertgeerts B; Rodondi N
BMJ; 2022 May; 377():e069116. PubMed ID: 35508321
[TBL] [Abstract][Full Text] [Related]
26. Race/ethnic and sex differences in the initiation of non-statin lipid-lowering medication following myocardial infarction.
Colvin CL; Poudel B; Bress AP; Derington CG; King JB; Wen Y; Chen L; Bittner V; Brown TM; Monda KL; Mues KE; Rosenson RS; Jackson EA; Muntner P; Colantonio LD
J Clin Lipidol; 2021; 15(5):665-673. PubMed ID: 34452823
[TBL] [Abstract][Full Text] [Related]
27. Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes.
Gencer B; Koskinas KC; Räber L; Karagiannis A; Nanchen D; Auer R; Carballo D; Carballo S; Klingenberg R; Heg D; Matter CM; Lüscher TF; Rodondi N; Mach F; Windecker S
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29122809
[TBL] [Abstract][Full Text] [Related]
28. Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified.
Baum SJ; Wade RL; Xiang P; Arellano J; Cerezo Olmos C; Nunna S; Chen CC; Carter CM; Desai NR
Ther Clin Risk Manag; 2019; 15():1325-1332. PubMed ID: 32009789
[TBL] [Abstract][Full Text] [Related]
29. Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease.
Albosta MS; Grant JK; Taub P; Blumenthal RS; Martin SS; Michos ED
Vasc Health Risk Manag; 2023; 19():421-431. PubMed ID: 37434791
[TBL] [Abstract][Full Text] [Related]
30. An estimation of the consequences of reinforcing the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines on current lipid-lowering treatment in patients with type 2 diabetes in tertiary care-a SwissDiab study.
Singeisen H; Renström F; Laimer M; Lehmann R; Bilz S; Brändle M
Eur J Prev Cardiol; 2023 Oct; 30(14):1473-1481. PubMed ID: 37226890
[TBL] [Abstract][Full Text] [Related]
31. Proposed low-density lipoprotein cholesterol goals for secondary prevention and familial hypercholesterolemia in India with focus on PCSK9 inhibitor monoclonal antibodies: Expert consensus statement from Lipid Association of India.
Puri R; Mehta V; Duell PB; Nair D; Mohan JC; Yusuf J; Dalal JJ; Mishra S; Kasliwal RR; Agarwal R; Mukhopadhyay S; Wardhan H; Khanna NN; Pradhan A; Mehrotra R; Kumar A; Puri S; Muruganathan A; Sattur GB; Yadav M; Singh HP; Agarwal RK; Nanda R
J Clin Lipidol; 2020; 14(2):e1-e13. PubMed ID: 32089456
[TBL] [Abstract][Full Text] [Related]
32. A Clinical Guide to Combination Lipid-Lowering Therapy.
Russell C; Sheth S; Jacoby D
Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190
[TBL] [Abstract][Full Text] [Related]
33. Benefits and drawbacks of statins and non-statin lipid lowering agents in carotid artery disease.
Paraskevas KI; Gloviczki P; Antignani PL; Comerota AJ; Dardik A; Davies AH; Eckstein HH; Faggioli G; Fernandes E Fernandes J; Fraedrich G; Geroulakos G; Golledge J; Gupta A; Gurevich VS; Jawien A; Jezovnik MK; Kakkos SK; Knoflach M; Lanza G; Liapis CD; Loftus IM; Mansilha A; Nicolaides AN; Pini R; Poredos P; Proczka RM; Ricco JB; Rundek T; Saba L; Schlachetzki F; Silvestrini M; Spinelli F; Stilo F; Suri JS; Svetlikov AV; Zeebregts CJ; Chaturvedi S; Veith FJ; Mikhailidis DP
Prog Cardiovasc Dis; 2022; 73():41-47. PubMed ID: 35605696
[TBL] [Abstract][Full Text] [Related]
34. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
[TBL] [Abstract][Full Text] [Related]
35. Lipid Modification to Reduce Cardiovascular Risk in Secondary Prevention Patients with Special Emphasis on PCSK9 Inhibitor Requirement: An Analysis Based on Delphi Panel Approach.
Kızılırmak P; Öngen Z; Güleç S; Kayıkçıoğlu M; Kılıçkap M; Abacı A; Özer N; Aydoğdu S; Temizhan A; Yılmaz MB; Bozkurt E; Dölek B; Tokgözoğlu L
Turk Kardiyol Dern Ars; 2022 Dec; 50(8):554-560. PubMed ID: 35976247
[TBL] [Abstract][Full Text] [Related]
36. Arterial stiffness improvement after adding on PCSK9 inhibitors or ezetimibe to high-intensity statins in patients with familial hypercholesterolemia: A Two-Lipid Center Real-World Experience.
Mandraffino G; Scicali R; Rodríguez-Carrio J; Savarino F; Mamone F; Scuruchi M; Cinquegrani M; Imbalzano E; Di Pino A; Piro S; Rabuazzo AM; Squadrito G; Purrello F; Saitta A
J Clin Lipidol; 2020; 14(2):231-240. PubMed ID: 32111581
[TBL] [Abstract][Full Text] [Related]
37. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
[TBL] [Abstract][Full Text] [Related]
38. More- Versus Less-Intensive Lipid-Lowering Therapy.
Toyota T; Morimoto T; Yamashita Y; Shiomi H; Kato T; Makiyama T; Nakagawa Y; Saito N; Shizuta S; Ono K; Kimura T
Circ Cardiovasc Qual Outcomes; 2019 Aug; 12(8):e005460. PubMed ID: 31412729
[TBL] [Abstract][Full Text] [Related]
39. Barriers to prescribing proprotein convertase subtilisin-kexin type 9 inhibitors after coronary revascularisation.
Nguy J; Hitchen SA; Lan NSR; Dwivedi G; Larbalestier R; Yeap BB; Fegan PG
Intern Med J; 2023 Jun; 53(6):994-1001. PubMed ID: 35112773
[TBL] [Abstract][Full Text] [Related]
40. Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines.
Koskinas KC; Gencer B; Nanchen D; Branca M; Carballo D; Klingenberg R; Blum MR; Carballo S; Muller O; Matter CM; Lüscher TF; Rodondi N; Heg D; Wilhelm M; Räber L; Mach F; Windecker S
Eur J Prev Cardiol; 2021 Mar; 28(1):59-65. PubMed ID: 33755142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
